WASHINGTON — The U.S. is facing a crisis in how to deliver cancer care, as the baby boomers reach their tumor-prone years and doctors have a hard time keeping up with complex new treatments, government advisers reported Tuesday. WASHINGTON —
WASHINGTON — The U.S. is facing a crisis in how to deliver cancer care, as the baby boomers reach their tumor-prone years and doctors have a hard time keeping up with complex new treatments, government advisers reported Tuesday.
The caution comes even as scientists are learning more than ever about better ways to battle cancer, and developing innovative therapies to target tumors.
And while doctors try to optimize treatment, the Institute of Medicine found “daunting” barriers to achieving high-quality care for all patients. Overcoming those challenges will require changes to the health care system, and savvier consumers.
But too often, decisions about cancer treatments aren’t based on good evidence, and patients may not understand their choices and what to expect, the panel found. For example, some studies suggest two-thirds or more of cancer patients with poor prognoses incorrectly believe the treatments they receive could cure them.
Topping the list of recommendations is finding ways to help patients make more informed decisions, with easy-to-understand information on the pros, cons and costs of different treatments.
The risk of cancer increases with age, and older adults account for just over half of the 1.6 million new cases diagnosed each year. By 2030, new diagnoses are expected to reach 2.3 million a year as the population ages. The report warns there may not be enough oncology specialists to care for them.
Perhaps a bigger concern is the growing complexity of care. Increasingly, scientists are finding genetic differences inside tumors that help explain why one person’s cancer is more aggressive than another’s. More importantly, that also means certain cancer drugs will work for, say, lung cancer in one person but not the next.
It’s not just a matter of knowing the latest treatments, but deciding if they’re worth it for an individual patient. Consider: Of 13 cancer treatments approved by the Food and Drug Administration last year, only one was proven to extend survival by more than six months, the report said. The drugs all cost more than $5,900 for each month of treatment.
For older adults, treatment decisions may be even more complicated — because the studies that test different therapies don’t include enough people over age 65, who tend to have multiple health problems along with cancer, Ganz explained.
Nor are cancer teams doing a good enough job in educating and training patients’ loved ones to offer the at-home care that many need for long stretches of time, she said.
The Institute of Medicine advises the government about health issues. Among its recommendations are: more research to tease out how to best treat different patients; new strategies to help doctors keep up with that evidence; and development of tools to help communicate the choices to patients so they understand what really may happen to them.
